Published in Gene Therapy Weekly, April 24th, 2008
"As a result, prognosis has been poor for patients with metastatic RCC (mRCC). A better understanding of the pathogenesis of RCC has led to the development and application of therapies targeted at key molecules involved in angiogenesis, which is an integral part of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.